Literature DB >> 10383624

Native human neocortex release-regulating dopamine D2 type autoreceptors are dopamine D2 subtype.

E Fedele1, G Fontana, C Munari, M Cossu, M Raiteri.   

Abstract

Dopamine (DA) autoreceptors expressed at DA nerve terminals regulate DA release. Considerable evidence has indicated that, in rodents, these autoreceptors belong to the D2 type of the DA receptor family, which, in turn, comprises the D2, D3 and D4 subtypes. We investigated here, for the first time, the subclassification of native human DA autoreceptors by studying the release of [3H]DA evoked by electrical stimulation in fresh human neocortical slices. The results have been compared with those obtained in three animal systems: rat neocortical and striatal slices and rat mesencephalic neuronal cultures. In human neocortical slices, the D2/D3 receptor agonist quinpirole (1 nM-10 microM) inhibited tritium release with a calculated EC50 of 17 nM and a maximal inhibition of approximately 75% reached at 1 microM. In the presence of the D2/D3 receptor antagonist (-)-sulpiride (0.1 and 1 microM), the concentration-response curve of quinpirole was shifted to the right, and the apparent pA2 mean value was 8.5 (8.14-8.77); on the other hand, the inhibitory effects of quinpirole were not affected by the D3 receptor-selective antagonist [7-N,N-dipropylamino-5,6,7, 8-tetrahydro-naphtho(2,3b) dihydro,2,3-furane] (S 14297) and the D4 receptor-selective antagonist 3-(4-[4-chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo [2,3-b]pyridine (L-745,870) (0.01-1 microM in each case). Superimposable results have been obtained when the release was elicited from rat striatal slices or dopamine mesencephalic neurons in culture, whereas quantitative differences emerged in the case of rat cortical slices. It is concluded that in human brain, as well as in rat brain, the release of DA in the terminal region of midbrain dopaminergic neurons is regulated through autoreceptors of the D2 subtype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383624     DOI: 10.1046/j.1460-9568.1999.00651.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  4 in total

1.  Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression.

Authors:  Neil M Richtand; Yanhong Liu; Rebecca Ahlbrand; Juliana R Sullivan; Amy Hauck Newman; Robert K McNamara
Journal:  Synapse       Date:  2010-08       Impact factor: 2.562

2.  Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.

Authors:  B Weber; E Schlicker; P Sokoloff; H Stark
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

3.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

4.  Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.

Authors:  Angela Deutschländer; Christian la Fougère; Kai Boetzel; Nathalie L Albert; Franz-Josef Gildehaus; Peter Bartenstein; Guoming Xiong; Paul Cumming
Journal:  Neuroimage Clin       Date:  2016-06-09       Impact factor: 4.881

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.